Sage Therapeutics Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Sage Therapeutics's estimated annual revenue is currently $95.9M per year.
- Sage Therapeutics received $575.0M in venture funding in February 2018.
- Sage Therapeutics's estimated revenue per employee is $155,000
- Sage Therapeutics's total funding is $193M.
- Sage Therapeutics has 619 Employees.
- Sage Therapeutics grew their employee count by -12% last year.
- Sage Therapeutics currently has 18 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Cell Signaling ...||$75.6M||488||N/A||N/A|
What Is Sage Therapeutics?
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage's lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Kate Jurcik||Senior Director Regulatory Affairs Advertising And Promotion|
|Kimi Iguchi||Chief Financial Officer|
|Jim Doherty||Chief Research Officer|
|Jeffrey Jonas||Ceo And Director|
|Stephen Kanes||Chief Medical Officer|
|Brian O'Donnell||Associate Director, Brand Medical Education|
|Christopher Galli||Director, Analytical Development|
|Dan Horne||Principal Scientist|
|Jeff Kasten||Senior Director, Head Of New Product Planning|
|Jennifer McDaniel||Associate Director, Clinical Data Management|
Sage Therapeutics News
Sage Therapeutics Announces the New England Journal of Medicine Publishes Data from Phase 2 Trial with SAGE-217 in Major Depressive ...
Atika Capital Management LLC lowered its position in SAGE Therapeutics Inc (NASDAQ:SAGE) by 26.7% in the second quarter, according to ...
With the previous 100-day trading volume average of 397159 shares, Sage Therapeutics (SAGE) recorded a trading volume of 364280 shares, ...
Sage Therapeutics Funding
|2013-10-17||$20.0M||B||ARCH Venture Partners||Article|
|2015-04-15||$115.0M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2015-04-22||$138.0M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2017-11-15||$345.0M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2018-02-09||$575.0M||Undisclosed||J.P. Morgan Securities LLC||Article|
Sage Therapeutics Executive Hires
|2011-12-02||Albert J. Robichaud||Chief Scientific Officer||Article|
|2014-05-06||Thomas D. Anderson||Chief Commercial Strategy Officer||Article|
|2017-04-25||Michael Cloonan||Chief Business Officer||Article|